PATENT

Attorney Docket No.: 47234-0003-00US

Application No. 10/500,841

Amendment Dated: February 25, 2008

REMARKS

The present amendments correct an error in translation of the Japanese priority document, JP 2002-2056. The amendments change "neovascularization accelerator" to "neovascularization *inhibitor*." The amendments are supported in the priority document, as well as by the language in the paragraph at page 23, line 20, through page 24, line 13, of the specification. For instance, the paragraph is directed, in part, to "(a) a compound showing a neovascularization *inhibiting* action in the above-mentioned screening method" (page 23, line 24), "a compound *suppressing* expression of the above-mentioned peptide or protein having a neovascularization action" (page 24, line 2), etc. For these reasons, the amendments do not add impermissible new matter. Entry and consideration of the amendments are respectfully requested.

CONCLUSION

Should the Examiner have any questions or comments regarding Applicants' amendments or response, he is asked to contact Applicants' undersigned representative at the telephone number below. Please direct all correspondence to the below-listed address.

If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0573. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is respectfully requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date: Febraury 25, 2008

Brian K. Lathrop, Ph.D., Esq.

Registration No. 43,740

DRINKER BIDDLE & REATH LLP

1500 K Street, NW, Suite 1100 Washington, DC 20005-1209

Tel: (202) 842-8862 Fax: (202) 842-8465